Press Releases

DNAtrix Collaborators Present Data on a Novel Oncolytic Adenovirus Expressing OX40 Ligand that Promotes Antitumor Immunity

Posted on June 16, 2015

Houston, TX – June 16, 2015. DNAtrix, Inc., a leader in oncolytic virus therapy, has announced that Juan Fueyo, M.D., professor in the Department of Neuro-Oncology and Director of the.. read more

DNAtrix Awarded Most Promising Life Science Company at 2015 Texas Life Science Forum

Posted on June 8, 2015

Houston, TX – DNAtrix was named one of the Most Promising Life Science Companies at the 2015 Texas Life Science Forum held in Houston, Texas on May 20, 2015. The.. read more

Alcyone Lifesciences and DNAtrix Enter Clinical Collaboration for Brain Cancer

Posted on May 20, 2015

Collaboration Combines Companies’ Expertise in Oncolytic Virus Therapy and Targeted Drug Delivery Lowell, MA and Houston, TX – May 19, 2015. Alcyone Lifesciences, Inc., a leader in neural intervention systems.. read more

DNATRIX COMPLETES $20 MILLION SERIES B FINANCING

Posted on October 14, 2014

San Diego, Calif.  –October 14, 2014 – DNAtrix, a clinical-stage oncolytic immunotherapy company, announced that it has completed a $20M Series B equity financing.  New investor Morningside Ventures led the.. read more

FDA GRANTS ORPHAN DRUG DESIGNATION TO DNATRIX’S DNX-2401 FOR THE TREATMENT OF MALIGNANT GLIOMA

Posted on October 7, 2014

SAN DIEGO, CA. – October 7, 2014 – DNAtrix, Inc., experts in oncolytic virus development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation.. read more